ESMO 2026 | Insights in Phase I trials assessing T-cell engagers for metastatic ovarian cancer
Kaissa Ouali, MD, Institut Gustave Roussy, Villejuif, France, discusses the retrospective ENGAGE-OV study assessing the clinical activity and molecular predictors of T-cell engagers in patients with heavily pretreated metastatic ovarian cancer treated in Phase I trials. Clinical benefit was observed in a majority of patients, with an acceptable safety profile and predominantly low-grade cytokine release syndrome. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
As I said, I think this is a new kind of drug that is going to change the landscape in ovarian carcinoma. And we now have multiple trials with multiple targets that actually are being evaluated in phase one. And what we looked at is first the toxicity profile. We see that most of the drugs that were being evaluated are manageable with low-grade CRS. And what we looked at also is the molecular biology of the tumors to see if we actually could see some features that could tell us, well, this patient is going to have a better response...
As I said, I think this is a new kind of drug that is going to change the landscape in ovarian carcinoma. And we now have multiple trials with multiple targets that actually are being evaluated in phase one. And what we looked at is first the toxicity profile. We see that most of the drugs that were being evaluated are manageable with low-grade CRS. And what we looked at also is the molecular biology of the tumors to see if we actually could see some features that could tell us, well, this patient is going to have a better response. We didn’t see anything, but interestingly, this is the first study that showed that the patients who seemed to have what we call clonal hematopoiesis seem to respond better than other patients. So this will be evaluated further in a prospective study.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
